https://www.selleckchem.com/pr....oducts/ripasudil-k-1
Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are markers of systemic inflammation associated with poor outcome in several solid tumours. We retrospectively investigated the prognostic role of PLR and, secondly, NLR in mCRPC patients treated with Abiraterone Acetate (AA) or Enzalutamide (E), both in pre- and post-docetaxel setting. 225 mCRPC patients treated with AA or E with basal blood count were divided in three groups according to PLR (PLR1 128; PLR2 128-190; PLR 19 and in two groups a
Like
Comment
Share
